P58 The use of a multi-analyte immunoassay panel (MAIP) to detect potential prognostic biomarkers associated with 2-month progression free survival rate in patients treated with Enzastaurin as 2nd and 3rd line therapy of NSCLC
Cleverly A, Bepler G, Oh Y, Burris H, Herbst R, Lahn M. P58 The use of a multi-analyte immunoassay panel (MAIP) to detect potential prognostic biomarkers associated with 2-month progression free survival rate in patients treated with Enzastaurin as 2nd and 3rd line therapy of NSCLC. European Journal Of Cancer Supplements 2007, 5: 30. DOI: 10.1016/s1359-6349(08)70079-x.Peer-Reviewed Original Research